Bone Biologics Corp
BBLGWNasdaq
$14.50
↑ +16.5%Jun 22 close · end-of-day
Price
1Y↑ +34.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$26.0M
Enterprise Value
$26.0M
P/E
—
P/S
—
P/B
5.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$2.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-61.2%
ROIC
-50.8%
Debt / Equity
—
Net Cash
—
Return 1Y
-3.3%
Company profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
- CEO
- Jeffrey Frelick
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 2
- Headquarters
- Massachusetts
- Website
- bonebiologics.com
Earnings
BBLGW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.43↓ -77.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$825,014.00 | -$1.1M | -$3.7M | -$9.4M | -$4.2M | -$3.2M |
| Net income | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| Diluted EPS | — | — | -$31.15 | -$34.01 | -$28.96 | -$2.65 |
| Operating cash flow | -$426,933.00 | -$1.2M | -$3.6M | -$9.6M | -$4.1M | -$2.7M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -0.1% | — | — | — | — | — |
| Net margin | -0.2% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$809,665.00 | -$951,021.00 | -$1.6M | -$1.0M | -$748,075.00 | -$715,274.00 | -$733,107.00 | -$805,054.00 |
| Net income | -$783,733.00 | -$941,002.00 | -$1.5M | -$1.0M | -$740,519.00 | -$666,737.00 | -$684,643.00 | -$765,988.00 |
| Diluted EPS | -$4.02 | -$14.21 | -$9.42 | -$1.92 | -$1.33 | -$0.37 | $0.97 | -$0.43 |
| Operating cash flow | -$895,865.00 | -$572,162.00 | -$1.4M | -$926,125.00 | -$458,879.00 | -$591,384.00 | -$714,762.00 | -$804,282.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Sep 26, 2023
Sep 13, 2023
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.